ETHOS TECHNOLOGIES INC CL-A (LIFE) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:LIFE • US0021202025

13.15 USD
+0.42 (+3.3%)
At close: Feb 4, 2026
12.99 USD
-0.16 (-1.22%)
After Hours: 2/4/2026, 8:00:03 PM

LIFE Key Statistics, Chart & Performance

Key Statistics
Market Cap898.86M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares68.35M
Float67.23M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07
IPO2015-05-07
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
LIFE short term performance overview.The bars show the price performance of LIFE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months

LIFE long term performance overview.The bars show the price performance of LIFE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of LIFE is 13.15 USD.

ETHOS TECHNOLOGIES INC CL-A / LIFE Daily stock chart

LIFE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to LIFE.


Chartmill TA Rating
Chartmill Setup Rating

LIFE Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

LIFE Forecast & Estimates

11 analysts have analysed LIFE and the average price target is 25.09 USD. This implies a price increase of 90.81% is expected in the next year compared to the current price of 13.15.


Analysts
Analysts81.82
Price Target25.09 (90.8%)
EPS Next YN/A
Revenue Next YearN/A

LIFE Ownership

Ownership
Inst Owners69.81%
Ins Owners12.06%
Short Float %N/A
Short RatioN/A

LIFE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.96398.827B
AMGN AMGEN INC16.25182.324B
GILD GILEAD SCIENCES INC16.37177.765B
VRTX VERTEX PHARMACEUTICALS INC23.11118.135B
REGN REGENERON PHARMACEUTICALS16.6879.79B
ALNY ALNYLAM PHARMACEUTICALS INC49.1446.476B
INSM INSMED INC N/A33.518B
NTRA NATERA INC N/A31.422B
BIIB BIOGEN INC12.0125.931B
UTHR UNITED THERAPEUTICS CORP16.3820.594B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About LIFE

Company Profile

LIFE logo image aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 65 full-time employees. The company went IPO on 2015-05-07. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. The company is also advancing its preclinical pipeline of tRNA synthetases and NRP2. The company has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.

Company Info

ETHOS TECHNOLOGIES INC CL-A

10240 Sorrento Valley Road, Suite 300

San Diego CALIFORNIA 92121 US

CEO: Sanjay S. Shukla

Employees: 65

LIFE Company Website

Phone: 18587318389

ETHOS TECHNOLOGIES INC CL-A / LIFE FAQ

What does ETHOS TECHNOLOGIES INC CL-A do?

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 65 full-time employees. The company went IPO on 2015-05-07. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. The company is also advancing its preclinical pipeline of tRNA synthetases and NRP2. The company has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.


Can you provide the latest stock price for ETHOS TECHNOLOGIES INC CL-A?

The current stock price of LIFE is 13.15 USD. The price increased by 3.3% in the last trading session.


Does LIFE stock pay dividends?

LIFE does not pay a dividend.


How is the ChartMill rating for ETHOS TECHNOLOGIES INC CL-A?

LIFE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Who owns ETHOS TECHNOLOGIES INC CL-A?

You can find the ownership structure of ETHOS TECHNOLOGIES INC CL-A (LIFE) on the Ownership tab.